Capricor Therapeutics (NASDAQ:CAPR) Trading Up 11% – Time to Buy?

Capricor Therapeutics, Inc. (NASDAQ:CAPR) traded up 11% during trading on Thursday . The company traded as high as $9.73 and last traded at $9.4990. Approximately 1,539,920 shares changed hands during trading, a decline of 49% from the average session volume of 3,049,009 shares. The stock had previously closed at $8.56.

Key Headlines Impacting Capricor Therapeutics

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: Capricor will present HOPE-3 and open-label extension data for deramiocel at the World Muscle Society Congress from September 29 to October 3. The late-breaking data will include delayed-start and natural-history analyses submitted in a recent major amendment to the biologics license application. The FDA’s PDUFA target action date is November 22, 2026, giving investors a near-term regulatory catalyst. Capricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data
• Positive Sentiment: B. Riley Financial raised Capricor to “Buy,” while the reported analyst consensus price target was increased to $21.42. These ratings suggest some analysts see substantial recovery potential following the stock’s earlier decline. Capricor Therapeutics Raised to Buy at B. Riley Financial
• Neutral Sentiment: Several law firms are soliciting investors to seek lead-plaintiff status by September 28 in a pending federal securities class action covering purchases made primarily between December 17, 2025, and July 26, 2026. The notices repeat allegations concerning HOPE-3 trial blinding, protocol procedures and differences between the final protocol and statistical analysis plan; these are allegations, not findings of wrongdoing. CAPR Deadline Alert
• Negative Sentiment: The volume of lawsuit announcements reinforces legal, reputational and potential financial uncertainty surrounding Capricor after the reported sharp stock decline following FDA briefing documents and an adverse advisory committee vote. Investors may remain cautious ahead of the FDA decision and upcoming trial-data presentation. CAPR Upcoming Deadline

Analyst Ratings Changes

CAPR has been the topic of several research analyst reports. Oppenheimer raised shares of Capricor Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, August 25th. B. Riley Financial upgraded Capricor Therapeutics from a “neutral” rating to a “buy” rating and upped their price objective for the company from $5.00 to $21.00 in a research note on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Friday, September 11th. HC Wainwright reiterated a “neutral” rating on shares of Capricor Therapeutics in a report on Monday, July 27th. Finally, JonesTrading downgraded shares of Capricor Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, July 31st. Five research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $30.25.

Capricor Therapeutics Stock Up 10.3%

The company has a market capitalization of $549.13 million, a P/E ratio of -3.85 and a beta of 0.72. The business has a 50 day simple moving average of $10.23 and a 200-day simple moving average of $22.77.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings data on Thursday, August 13th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.11). Equities analysts forecast that Capricor Therapeutics, Inc. will post -1.71 EPS for the current fiscal year.

Insider Activity at Capricor Therapeutics

In other Capricor Therapeutics news, CFO Anthony Bergmann sold 24,100 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $30.38, for a total value of $732,158.00. Following the sale, the chief financial officer owned 11,223 shares in the company, valued at approximately $340,954.74. This trade represents a 68.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 25,000 shares of company stock valued at $759,158 in the last quarter. 9.20% of the stock is currently owned by company insiders.

Institutional Trading of Capricor Therapeutics

Several large investors have recently added to or reduced their stakes in CAPR. ACT Capital Management LLC acquired a new position in Capricor Therapeutics during the 4th quarter worth $43,000. KBC Group NV acquired a new position in shares of Capricor Therapeutics during the first quarter valued at $44,000. Allworth Financial LP raised its stake in shares of Capricor Therapeutics by 5,021.5% during the fourth quarter. Allworth Financial LP now owns 3,329 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 3,264 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Capricor Therapeutics in the first quarter worth about $193,000. Finally, ProShare Advisors LLC acquired a new stake in Capricor Therapeutics in the fourth quarter worth about $203,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a biotechnology company focused on developing cell- and exosome-based therapies for serious diseases. The company’s programs are designed to use regenerative medicine and targeted delivery technologies to address conditions with limited treatment options.

Its leading therapeutic candidate is deramiocel, also known as CAP-1002, an allogeneic cell therapy derived from cardiosphere-derived cells. The program has been studied primarily for Duchenne muscular dystrophy, a genetic disorder that causes progressive muscle weakness and cardiac complications.